ArticlePloS one2025
Exploring in-vitro antioxidant, cytotoxicity, hemolytic, thrombolytic and anticancer potentials of Ochthochloa compressa (Forssk.) Hilu.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bottle Gourd (Scientifica · 2026Article
- Chemical finger-printing, antioxidant activity and in silico validation of phytometabolites of Octhochloa compressa.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlobally, medicinal plants are found therapeutically very effective against many illnesses. Still there is huge demand of plant based alternate medicines in market. The therapeutic potential of many plants is still unexplored. One such medicinal plant is Ochthochloa compressa, a member of family Poaceae commonly located in Cholistan desert of Bahawalpur, Pakistan. PURPOSE: The purpose of this study is to evaluate some pharmacological properties of plant which include; exploration of cytotoxic, hemolytic, antioxidants, anticancer and thrombolytic phytochemicals from various extracts of O. compressa. STUDY
designThis study includes in-vitro experimental study design. METHODOLOGY: O. compressa extracts were prepared on the basis of polarity. The extracts were subjected for screening of phytochemicals and determining the total bioactive contents. Each extract was tested for cytotoxicity, hemolytic, antioxidant, thrombolytic and anticancer potential through cytotoxic and cell viability assays; MTT, morphology, crystal violet, trypan blue and scratch. GCMS analysis of each extract was done for identification of phytocompounds. In-silico molecular docking was performed against phytocompounds of EtOAc extract and further studied to visualize interactions between the compounds and coagulation factor XI. Compounds which showed maximum binding affinity were used in ADMET studies.
resultsThe phytochemical screening and GCMS analysis revealed various phytochemicals in plant extracts. HET CAM assay revealed that all extracts were non and/or weak irritant except DCM which was moderately irritant. The least hemolytic activity was observed in all extracts, which proved that the plant is non-toxic, non-hemolytic and safe to use. The extracts showed a good antioxidant potential and order was as; MtOH > Aq > n-Hex > EtOAc > DCM. Promising anticancer potential was observed by extracts of this plant against HepG2 cell line and order of activity was as; n-Hex > MtOH = Aq = DCM > EtOAc. Notably high thrombolytic potential was observed by all extracts especially from EtOAc (96.2 ± 0.88) which was almost equal to Streptokinase (99.3 ± 0.41). Phytocompounds of EtOAc identified by GCMS analysis showed significant binding affinity with coagulation factor XI protein, and upon evaluation of ADMET profile, all compounds followed Lipinski's rule of five, being suitable for orally administration.
conclusionO. compressa extracts are good source of antioxidant, anticancer and thrombolytic agents. The plant is non-toxic and non-hemolytic as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.